Bloomberg Billionaires Index

View profiles for each of the world’s 500 richest people, see the biggest movers, and compare fortunes or track returns.

#100 Dilip Shanghvi $12.4B

Random fact: Says "money is the outcome of my work and is incidental."

Overview

Shanghvi is the founder and largest shareholder of Sun Pharmaceutical Industries, the world's fifth largest generic drugmaker. The Mumbai-based company serves more than 150 countries and has over 30,000 employees. He also has interests in Sun Pharma Advanced Research, Natco Pharma and BioLight Life Sciences.

As of July 21, 2017:
Last change -$374M (-2.9%)
YTD change -$429M (-3.4%)
Industry Health Care
Biggest asset SUNP IN Equity
Citizenship India
Age 61
Wealth Self-made
View net worth over:   Max 1 year 1 quarter 1 month 1 week

Relative Value

Dilip Shanghvi's net worth of $12.4B can buy ...

0
troy ounces of gold
0
barrels of crude oil

... and is equivalent to ...

0%
of the GDP of the United States
0%
of the total wealth of the 500 richest people in the world
0%
of the top 100 U.S. college endowments
0%
of the top 200 U.S. executives’ total awarded compensation
0%
of U.S. existing home sales
0
times the median U.S. household income

Latest News

Net Worth Summary

Cash
Private asset
Public asset
Misc. liabilities
Confidence rating:

The majority of Shangvhi's wealth comes from his 54 percent equity interest in generics drugmaker Sun Pharmaceutical Industries. He holds the shares directly, through holding companies, trusts and family members, according to a June 2017 filing to the Bombay Stock Exchange. Shares held by his family are credited to Shanghvi to reflect his status as founder and managing director. Sun Pharma is the world's fifth largest speciality generic pharmaceutical company, according to its website in March 2017.

He also has 67 percent of Sun Pharma Advanced Research, the research and development arm of the drugmaker. He controls shares in the companies directly and through promoter groups, which are all attributed to him to reflect his status as founder. Pledged shares have been excluded from the calculation of his net worth.

Outside of Sun Pharma, he owns 14 percent of BioLight Life Sciences, which develops drugs and medical technology. He also has a 3 percent interest in Indian drugmaker Natco Pharma. Shangvhi also owns 19 percent of Suzlon Energy, Asia’s second-largest maker of wind turbines, a stake he purchased for $289 million in February 2015.

The value of Shanghvi's cash holdings is based on an analysis of dividends, insider transactions, market performance, taxes and charitable contributions.

Frederick Castro, a Sun Pharma spokeswoman, declined to comment on Shanghvi's net worth calculation.

Biography

Birthdate: 1955
Family: Married, 2 children
Education: 1982, University of Calcutta, Bachelor's Degree

Born in 1955, Dilip Shanghvi was raised in Kolkata, where his father ran a pharmaceutical trading company selling branded and generic drugs. He earned a bachelor's degree in commerce from the University of Calcutta in 1982. Upon graduating, Shanghvi started Mumbai-based Sun Pharmaceutical Industries as a two-man operation selling a single drug, Lithosun, which is used to treat bipolar disease. His then-partner, Pradeep Ghosh, still works for Sun Pharma.

Shanghvi established the Pharma Advanced Research Center to speed the development of generic drugs in 1993. The next year, Sun Pharma sold shares on the Bombay and National Stock Exchange. The offering was oversubscribed 55 times.

Shanghvi then expanded into the U.S. generic drug industry, acquiring Detroit-based Caraco Pharmaceuticals in 1997. Caraco gave him access to the world's largest market for generic drugs, its distributors, and expertise in dealing with the Food and Drug Administration. In all, Shanghvi has bought 13 drugmakers since 1997, following a strategy of acquiring under-performing or unprofitable companies and merging their operations into Sun Pharma.

An unsuccessful six-year takeover battle for Taro Pharmaceutical started in 2007 when Shangvhi made a $454 million bid to acquire the Yakum, Israel-based drugmaker. Over the years, Sun Pharma eventually acquired a 61 percent stake in Taro after grappling with the company's founders for control, and offered to buy the rest for $367 million in October 2011. Sun withdrew the offer in February 2013 after shareholders held out for a higher price.

In May 2012, Shanghvi relinquished his position as chairman of Sun Pharma to his handpicked successor, Israel Makov, the former chief executive officer of Teva Pharmaceuticals, the world's largest generic drug maker. The billionaire took up the role of managing director of the company instead.

Sun Pharma then acquired domestic competitor Ranbaxy Laboratories in what was its biggest ever purchase and the largest in the pharmaceutical industry in Asia in 2014. The deal, which closed in March 2015, boosted the company's stock and made Shanghvi the world's richest pharmaceutical tycoon.

Milestones
  • 1955 Dilip Shantilal Shanghvi is born in Gujarat, India.
  • 1983 Creates Sun Pharmaceutical Industries in Kolkata.
  • 1989 Sun Pharma begins to sell products in India
  • 1994 Sun Pharma sells shares in an initial public offering.
  • 2007 Starts takeover battle for Taro Pharmaceutical.
  • 2010 Gains majority shareholding in Taro Pharmaceutical.
  • 2012 Names Israel Makov chairman of Sun Pharma.
  • 2014 Sun Pharma agrees to buy Ranbaxy for $3.2 billion in stock.
  • 2015 Overtakes Mukesh Ambani as India's richest person.
  • 2016 Agrees to purchase 14 prescription brands from Novartis in Japan.